Title A guideline for the diagnosis and management of polycythaemia vera A British Society for
Haematology Guideline Authors Mc Page 1 1 Title 1 A guideline for the diagnosis and …

Background Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many
myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative …

1Centre for Medical Education, Queen's University, Belfast, 2MRC Molecular Haematology
Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine …

In a previous study, we identified somatic mutations of SF3B1, a gene encoding a core
component of RNA splicing machinery, in patients with myelodysplastic syndrome (MDS) …

Mutations in cancer-associated genes drive tumour outgrowth, but our knowledge of the
timing of driver mutations and subsequent clonal dynamics is limited,–. Here, using whole …

Background Cancers result from the accumulation of somatic mutations, and their properties
are thought to reflect the sum of these mutations. However, little is known about the effect of …

Background Myeloproliferative neoplasms, such as polycythemia vera, essential
thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied …

Summary The JAK2V617F mutation is associated with distinct myeloproliferative neoplasms,
including polycythemia vera (PV) and essential thrombocythemia (ET), but it remains …

Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations in
JAK2, CALR or MPL, but the contribution of inherited factors is poorly characterized. Using a …

Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress
has been made in better understanding the molecular pathogenesis and which patients may …